Created in 2020, SPyDiag is a biotechnology start-up based on research from the universities of Tours and Amiens. The SPyDiag team is made up of complementary talents (5 co-founders, including 4 PhDs and a CEO, HEC, with solid healthcare business experience).
Worldwide, the number of kidney graft is increasing and reached almost 100.000 in 2023. BK nephropathy is a life-threatening disease which can conduct to kidney graft failure and return to dialysis. In the absence of specific antiviral treatment, early monitoring of BK polyomavirus (BKPyV) reactivation is mandatory to fine tune the immunosuppressive treatment. In this context, SPyDiag has developed UriFastBK assay, which is a LFIA assay developed to detect presence of BKPyV in urinary samples. UriFastBK is fast and easy to implement even at the bedside, less costly than qPCR.
At the same time, SPyDiag is developing a treatment using a bi-specific antibody capable of neutralizing the two main subtypes of the BKPyV (95% of patients). This innovative technology is based on humanized monoclonal antibodies specific to BKPyV subtypes I and IV (patent pending), from which the bi-specific antibody is constructed.
SPyDiag offers global disease management of BKPyV (diagnosis, monitoring and therapy) to improve quality of life for patients and save money for the healthcare system.
Learn more: www.spydiag.com